A peer-reviewed paper published in the International Journal of Molecular Sciences reports that Telomir-Zn significantly improved visual function, restored thickness across multiple retinal layers and reduced mitochondrial oxidative stress in a zebrafish model of mitochondrial dysfunction and age-related retinal degeneration.
Telomir Pharmaceuticals claims treatment produced dose-dependent increases in relative telomeric DNA content and restoration of altered DNA methylation at selected aging-associated CpG loci.
In complementary cellular and biochemical studies, the company reports Telomir-Zn increased intracellular zinc, reduced labile Fe2+ and potently inhibited multiple iron-dependent Jumonji C histone demethylases across KDM2, KDM5 and KDM6 families, with strongest activity against KDM5B (IC50 63 nM).
The company frames these results as evidence that modulation of intracellular metal homeostasis can influence epigenetic programs across disparate disease settings, while noting Telomir continues to advance Telomir-Zn under an FDA-cleared Investigational New Drug application for a Phase 1/2 trial in patients with advanced or metastatic triple-negative breast cancer.
